[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357003-105":59,"doc-detail-357003-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-has2-to-enhance-anti-tumor-immunity-in-pancreatic-cancer-via-pd-l1-regulation","Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation","","Pancreatic cancer presents poor prognosis and limited therapeutic options, while immunotherapy resistance limits durable benefit. This study shows HAS2 is markedly upregulated in pancreatic cancer and correlates with worse outcomes, reduced CD4+ and CD8+ T-cell infiltration, and shorter survival. Mechanistically, HAS2 stabilizes the immune checkpoint molecule PD-L1 by modulating K6- and K63-linked ubiquitination. HAS2 also activates AKT signaling to downregulate March4, an E3 ligase that normally suppresses PD-L1 stability, and in KPC mice HAS2 knockout reduces PD-L1, increases March4, enhances T-cell infiltration, and delays progression.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-has2-to-enhance-anti-tumor-immunity-in-pancreatic-cancer-via-pd-l1-regulation/357003/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-has2-to-enhance-anti-tumor-immunity-in-pancreatic-cancer-via-pd-l1-regulation/357003.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does HAS2 play in pancreatic cancer progression?","Question",{"text":113,"@type":114},"HAS2 is significantly upregulated in pancreatic cancer and is associated with poor prognosis and reduced T-cell infiltration, indicating it promotes immune evasion and tumor progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does HAS2 regulate PD-L1 stability?",{"text":118,"@type":114},"HAS2 stabilizes PD-L1 by modulating K6- and K63-linked ubiquitination, enhancing PD-L1 stability and suppressing immune responses.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the function of the HAS2–March4 axis in PD-L1 regulation?",{"text":122,"@type":114},"HAS2 activates AKT signaling to downregulate March4, an E3 ubiquitin ligase that negatively regulates PD-L1 stability, thereby facilitating PD-L1 stabilization.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},357003,1790211575,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","communications biology Article  \n\n| A Nature Portfolio journal |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s42003-026-10009-1](https://doi.org/10.1038/s42003-026-10009-1) |  |  |\n| Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation\u003Cbr> Check for updates |  |  |\n| Chuifang Kong1,7, Yanchun Fang2,7, Lili Shen3, Zhihua Shui1, Mengjie Lv 1, Xinyu Zhang1, Hanmeng Xu1, Xunxia Bao1, Pengwei Cao1, Wenjing Ding1, Tengfei Yu1, Shengming Ruan1, Juan Ran1, Jiangming Chen4, Juling Wang1, Dongsheng Hou5, Fubao Liu4, Yanping Wang 2 , Qiong Li 6  & Daoxiang Zhang 1  |  |  |\n| Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Recent advances in immunotherapy have shown potential for improving outcomes; however, therapeutic resistance remains a challenge. We demonstrate that HAS2 is signiﬁcantly upregulated in pancreatic cancer, andisassociated with poor prognosis, reduced inﬁltration of CD4⁺ and CD8⁺ T cells, and shorter survival. Mechanistically, HAS2 stabilizes PD-L1, a key immune checkpoint molecule, by modulating K6-and K63-linked ubiquitination, enhancing PD-L1 stability and suppressing immune responses. Our study further reveals that HAS2 activates the AKT signaling pathway to downregulate March4 expression, a critical E3 ubiquitin ligase that negatively regulates PD-L1 stability, thereby promoting PD-L1 stabilization. In vivo, HAS2 knockout in KPC mice reduces PD-L1 levels, increases March4 expression, enhances T cell inﬁltration, and delays cancer progression. Reduced collagen deposition in HAS2⁺/⁻ tumors further underscores its role in tumor microenvironment remodeling. Targeting the HAS2-March4-PD-L1 axis through HAS2 inhibition, anti-PD-L1 therapy, or March4 overexpression suppresses tumor growth and improves survival. |  |  |\n| Pancreatic cancer remains one of the most lethal malignancies, with a ﬁveyear survival rate below 10%1,2. Its aggressiveness is driven by both intrinsic tumor cell properties and a uniquely desmoplastic tumor microenvironment (TME)3. This dense and ﬁbrotic TME, characterized by abundant extracellular matrix (ECM) components, serves as a physical barrier to immune cell inﬁltration and therapy delivery while creating a protumorigenic niche that promotes tumor growth, invasion, and immune evasion4,5.\u003Cbr>Among the ECM components, hyaluronan (HA), a glycosaminoglycan, plays a pivotal role in shaping the pancreatic TME6. Elevated HA levels are a hallmark of pancreatic cancer, contributing to increased tissue stiffness, elevated interstitial pressure, and limited immune cell inﬁltration7–9. HA synthesis is catalyzed by the hyaluronan synthase (HAS) family, comprising HAS1, HAS2, and HAS310, 11. Of these isoforms, HAS2 is particularly critical due to its strong enzymatic activity and upregulation in various cancers, including pancreatic ductal adenocarcinoma (PDAC)12. HAS2 has been | implicated in driving tumor progression and therapeutic resistance by promoting ECM remodeling and immune evasion13. However, the molecular mechanisms by which HAS2 regulates immune escape remain poorly understood.\u003Cbr>Immune evasion is a deﬁning characteristic of pancreatic cancer14. The expression of immune checkpoint molecules, such as programmed deathligand 1 (PD-L1), enables tumor cells to suppress T cell-mediated immune responses, facilitating immune escape15–17. Emerging evidence suggests that HAS2 may regulate PD-L1 expression and contribute to immune suppression within the TME13, though the underlying mechanisms remain unclear. Moreover, the interplay between HAS2 and key regulatory molecules, such as E3 ubiquitin ligases, in controlling PD-L1 stability has not been fully elucidated.\u003Cbr>In this study, we investigate the HAS2-March4-PD-L1 regulatory axis in pancreatic cancer. We hypothesize that HAS2 promotes tumor progression and immune evasion by stabilizing PD-L1 protein levels through |  |\n\n1School of Life Sciences, Anhui medical Uni","cbCaildtWWi2uO3k","https://ap.wps.com/l/cbCaildtWWi2uO3k","pdf",4013990,12,"English","# Results\n## HAS2 expression is associated with poor prognosis and immune infiltration","[{\"question\":\"What role does HAS2 play in pancreatic cancer progression?\",\"answer\":\"HAS2 is significantly upregulated in pancreatic cancer and is associated with poor prognosis and reduced T-cell infiltration, indicating it promotes immune evasion and tumor progression.\"},{\"question\":\"How does HAS2 regulate PD-L1 stability?\",\"answer\":\"HAS2 stabilizes PD-L1 by modulating K6- and K63-linked ubiquitination, enhancing PD-L1 stability and suppressing immune responses.\"},{\"question\":\"What is the function of the HAS2–March4 axis in PD-L1 regulation?\",\"answer\":\"HAS2 activates AKT signaling to downregulate March4, an E3 ubiquitin ligase that negatively regulates PD-L1 stability, thereby facilitating PD-L1 stabilization.\"}]","Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation | PDF",1790128575,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2304a850511d1e54c6d6de8a29808aa6.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee93cefdc7a8c45bb3a21c1b75f35c45.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1fca1299daac1cc49f53dc8a2c003e1.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e50da2b7add38610ad4fb67b5516efa.webp",980,1301]